to determine whether the binding of bion 1 or a fragment thereof to u03b2 c receptor or fragment is inhibited the nature of these inhibitory compounds will not be limited and the methods used for a binding assay can be any one of the many techniques known to those skilled in the art such methods may include affinity selection chromatography ultrafiltration assays the scintillation proximity assay interfacial optical techniques the quartz crystal microbalance the jet ring cell interferometric assays using porous silicon to immobilise the receptor reference to such techniques can be found in woodbury et al 1999 which reference is incorporated herein in its entirety the range of therapeutic compounds may include peptides oligonucleotides or other small organic or inorganic molecules fig1 shows the results of screening 7 mer and 12 mer peptide libraries using soluble u03b2 c domain 4 supported on elisa plates the cell line bion 1 was deposited on the apr 29th 1998 in the american type culture collection atcc at 101801 university boulevard manassas va united states of america and has been designated atcc hb 12525 table i epitope mapping of bion 1 binding affinities of moab bion 1 tested on cos cells transfected with wild type u03b2c or mutants of u03b2c bion 1 kd 1c1 kd u03b2c wild type 49 3 4 4 u03b2c mutated in the b u2032 c u2032 loop m363a r364a 0 u2020 3 8 y365a 69 41 5 e366a 02 4 h367a 27 02 8.